Loading...
Publication
Papel do canabidiol na modulação da resposta imunitária
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 38210 | 720.43 KB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
O canabidiol (CBD), principal canabinoide não psicotrópico derivado da planta da canábis, recebeu aprovação da Food and Drug Administration e da Agência Europeia de Medicamentos para o tratamento de crises epiléticas pediátricas. No entanto, o CBD também tem efeitos anti-inflamatórios e imunomoduladores relevantes. Este trabalho tem como objetivo fazer uma revisão atual da literatura existente sobre os efeitos do CBD na modulação do sistema imunitário. No que concerne à modulação de citocinas e quimiocinas, o CBD exibe a capacidade de regular a resposta imunitária, resultando na redução da secreção de mediadores pró-inflamatórios. Essa regulação tem implicações importantes, especialmente em doenças autoimunes, uma vez que muitas dessas condições são desencadeadas ou exacerbadas por uma resposta inflamatória desregulada mediada por citocinas. Adicionalmente, o CBD exerce influência tanto sobre a imunidade inata quanto a adaptativa, afetando a funcionalidade de diversas categorias de células do sistema imunitário, como macrófagos e linfócitos. As evidências sugerem que o sistema endocanabinoide é um alvo proeminente para o tratamento de doenças inflamatórias e autoimunes, com destaque para a capacidade do CBD de modular o sistema endocanabinoide, o que, por sua vez, regula a resposta imunitária, diminuindo a libertação de citocinas inflamatórias e influenciando diversas células do sistema imunitário. No entanto, são ainda necessários estudos clínicos para estabelecer o papel terapêutico do CBD em doenças com uma forte componente inflamatória, tais como a esclerose múltipla e outras doenças autoimunes, cancro, asma e doenças cardiovasculares.
Cannabidiol (CBD), the primary non-psychotropic cannabinoid derived from the cannabis plant, has received approval from the Food and Drug Administration and the European Medicines Agency for the treatment of pediatric epileptic seizures. However, CBD also has relevant anti-inflammatory and immunomodulatory effects. This work aims to provide a current review of the existing literature on the effects of CBD on immune system modulation. Regarding the modulation of cytokines and chemokines, CBD demonstrates the ability to regulate the immune response, resulting in a reduction in the secretion of pro-inflammatory mediators. This regulation has important implications, especially in autoimmune diseases, as many of these conditions are triggered or exacerbated by dysregulated cytokine-mediated inflammation. Additionally, CBD influences both innate and adaptive immunity, impacting the functionality of various categories of immune system cells, including macrophages and lymphocytes. The evidence suggests that the endocannabinoid system is a prominent target for the treatment of inflammatory and autoimmune diseases, with a particular emphasis on CBD's ability to modulate the endocannabinoid system, which, in turn, regulates the immune response by reducing the release of pro-inflammatory cytokines and influencing various immune system cells. Nevertheless, clinical studies are still required to establish the therapeutic role of CBD in diseases with a strong inflammatory component, such as multiple sclerosis and other autoimmune diseases, cancer, asthma, and cardiovascular diseases.
Cannabidiol (CBD), the primary non-psychotropic cannabinoid derived from the cannabis plant, has received approval from the Food and Drug Administration and the European Medicines Agency for the treatment of pediatric epileptic seizures. However, CBD also has relevant anti-inflammatory and immunomodulatory effects. This work aims to provide a current review of the existing literature on the effects of CBD on immune system modulation. Regarding the modulation of cytokines and chemokines, CBD demonstrates the ability to regulate the immune response, resulting in a reduction in the secretion of pro-inflammatory mediators. This regulation has important implications, especially in autoimmune diseases, as many of these conditions are triggered or exacerbated by dysregulated cytokine-mediated inflammation. Additionally, CBD influences both innate and adaptive immunity, impacting the functionality of various categories of immune system cells, including macrophages and lymphocytes. The evidence suggests that the endocannabinoid system is a prominent target for the treatment of inflammatory and autoimmune diseases, with a particular emphasis on CBD's ability to modulate the endocannabinoid system, which, in turn, regulates the immune response by reducing the release of pro-inflammatory cytokines and influencing various immune system cells. Nevertheless, clinical studies are still required to establish the therapeutic role of CBD in diseases with a strong inflammatory component, such as multiple sclerosis and other autoimmune diseases, cancer, asthma, and cardiovascular diseases.
Description
Keywords
Cannabis sativa Canabidiol Sistema endocanabinoide Sistema imunitário Imunosupressão Inflamação Endocannabinoid system Immune system Immunosuppression Inflammation